Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Phase 1a/b, Single-Dose Study of ABBV-547 to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability in Adult Participants and Efficacy in Adult Participants

NCT07232004 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07232004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07232004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Phase 1a/b, Single-Dose Study of ABBV-547 to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability in Adult Participants and Efficacy in Adult Participants
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 24, 2025
Completion date
August 31, 2027
Enrollment
121 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer